Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Proteogenomics drives therapeutic hypothesis generation for precision oncology


Precision oncology has largely been driven by genomic profiling, but success so far has been limited. By combining genomic and proteomic analyses of tumours, proteogenomics holds promise in providing deeper mechanistic insights and generating therapeutic hypotheses to better match patients to targeted treatments than analysing each ‘ome in isolation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Proteogenomics drives therapeutic hypothesis generation for precision oncology.


  1. Blum, A., Wang, P. & Zenklusen, J. C. SnapShot: TCGA-analyzed tumors. Cell 173, 530 (2018).

    Article  CAS  Google Scholar 

  2. Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D. et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J. Clin. Oncol. 38, 3883–3894 (2020).

    Article  CAS  Google Scholar 

  3. Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).

    Article  CAS  Google Scholar 

  4. Mertins, P., Tang, L. C., Krug, K., Clark, D. J., Gritsenko, M. A., Chen, L. et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat. Protoc. 13, 1632–1661 (2018).

    Article  CAS  Google Scholar 

  5. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387 (2014).

    Article  CAS  Google Scholar 

  6. Wang, J., Mouradov, D., Wang, X., Jorissen, R. N., Chambers, M. C., Zimmerman, L. J. et al. Colorectal cancer cell line proteomes are representative of primary tumors and predict drug sensitivity. Gastroenterology 153, 1082–1095 (2017).

    Article  Google Scholar 

  7. Huang, C., Chen, L., Savage, S. R., Eguez, R. V., Dou, Y., Li, Y. et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell (2021).

  8. Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956–965 (2016).

    Article  CAS  Google Scholar 

  9. Wen, B., Li, K., Zhang, Y. & Zhang, B. Cancer neoantigen prioritization through sensitive and reliable proteogenomics analysis. Nat. Commun. 11, 1759 (2020).

    Article  CAS  Google Scholar 

  10. Satpathy, S., Jaehnig, E. J., Krug, K., Kim, B. J., Saltzman, A. B., Chan, D. W. et al. Microscaled proteogenomic methods for precision oncology. Nat. Commun. 11, 532 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations



J.T.L. and B.Z. drafted and revised the paper and approved the final version for publication.

Corresponding author

Correspondence to Bing Zhang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Data availability

Not applicable.

Completing interests

The authors declare no competing interests.

Funding information

This work was supported by grants U24 CA210954 from the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC), by a Cancer Prevention Institute of Texas (CPRIT) award RR160027, and by funding from the McNair Foundation. J.T.L is supported by grant T32 CA203690 from the Translational Breast Cancer Research Training Program. B.Z. is a CPRIT Scholar in Cancer Research and McNair Medical Institute Scholar.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lei, J.T., Zhang, B. Proteogenomics drives therapeutic hypothesis generation for precision oncology. Br J Cancer 125, 1–3 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links